Dyax Jumps on Positive Drug News

The company's new drug DX-88 showed it helps treat the hereditary skin disease angioedema

Dyax Corp. (DYAX) proved that its new drug DX-88 helps people who have the hereditary skin disease angioedema (HAE). The news sent the Cambridge, (Mass.) drug maker's shares flying -- touching a 52-week high of $6.95 before ending up 49.3% to $5.97 in heavy volume on the Nasdaq Apr. 13.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.